

Exhibit E

Bates	Custodian
Auro-MDL 2875-0089603	Johns, Blessy
Auro-MDL 2875-0089276	Johns, Blessy
Auro-MDL 2875-0089184	Johns, Blessy
Auro-MDL 2875-0085834	Burns, Daniel
Auro-MDL 2875-0092684	Gorijavolu, Prasad
Auro-MDL 2875-0092685	Gorijavolu, Prasad
Auro-MDL 2875-0089169	Johns, Blessy
Auro-MDL 2875-0089154	Johns, Blessy
Auro-MDL 2875-0089316	Johns, Blessy
Auro-MDL 2875-0080843	Burns, Daniel
Auro-MDL 2875-0080844	Burns, Daniel
Auro-MDL 2875-0080845	Burns, Daniel
Auro-MDL 2875-0080957	Burns, Daniel
Auro-MDL 2875-0080979	Burns, Daniel
Auro-MDL 2875-0080980	Burns, Daniel
Auro-MDL 2875-0080981	Burns, Daniel
Auro-MDL 2875-0080984	Burns, Daniel
Auro-MDL 2875-0081006	Burns, Daniel
Auro-MDL 2875-0081007	Burns, Daniel
Auro-MDL 2875-0081008	Burns, Daniel
Auro-MDL 2875-0081034	Burns, Daniel
Auro-MDL 2875-0081105	Burns, Daniel
Auro-MDL 2875-0081217	Jackowski, Jeff
Auro-MDL 2875-0081231	Jackowski, Jeff
Auro-MDL 2875-0081296	Gupta, Jasleen
Auro-MDL 2875-0081297	Gupta, Jasleen
Auro-MDL 2875-0081407	Jackowski, Jeff
Auro-MDL 2875-0081282	Jackowski, Jeff
Auro-MDL 2875-0081379	Gupta, Jasleen
Auro-MDL 2875-0109848	Meridian Consulting
Auro-MDL 2875-0086345	Burns, Daniel
Auro-MDL 2875-0086346	Burns, Daniel
Auro-MDL 2875-0085916	Burns, Daniel
Auro-MDL 2875-0092703	Gorijavolu, Prasad
Auro-MDL 2875-0102026	Johns, Blessy
Auro-MDL 2875-0102027	Johns, Blessy
Auro-MDL 2875-0095192	Johns, Blessy
Auro-MDL 2875-0097099	Johns, Blessy
Auro-MDL 2875-0083803	Bheminemi, Sudhir
Auro-MDL 2875-0095119	Johns, Blessy
Auro-MDL 2875-0095120	Johns, Blessy

Filename	Date
Valsartan Statement.doc	3/29/2012 1:03 AM
Cover letter.doc	3/29/2012 2:45 AM
valsartan tablets cover letter.doc	3/21/2012 9:02 AM
DEV-18-026.doc	3/15/2018 4:31 PM
Reduce Testing SOP-Final.DOC	3/27/2012 4:20 AM
Reduce Testing SOP Draft2.doc	3/29/2012 9:57 AM
Valsartan HCTZ tablets - FDA Query and Justification 120112.doc	1/12/2012 10:53 PM
Valsartan HCTZ tablets - FDA Query and Justification 120112.doc	1/12/2012 7:33 AM
Valsartan & Hydrochlorothiazide tablets Cover letter.doc	3/15/2012 7:15 AM
SOP-QA007.05 Equipment, Instruments and Facility Numbering System.doc	4/23/2018 12:12 PM
SOP-QA007-F01.01 REQUEST FORM.doc	11/9/2011 2:18 PM
SOP-QA007-F02.01 REQUEST FORM Delete.doc	11/9/2011 2:18 PM
Valsartan Attachment B - Drug Dear Recalling Firm.doc	2/28/2019 4:06 PM
Valsartan - Customer RECALL RESPONSE FORM with edits.docx	2/28/2019 4:26 PM
Valsartan - Wholesale RECALL RESPONSE FORM with edits.docx	2/28/2019 4:25 PM
DPress Release Form - rev 01Mar2019.doc	3/1/2019 9:41 AM
Valsartan Attachment B - Drug Dear Recalling Firm.doc	2/28/2019 4:06 PM
Valsartan - Customer RECALL RESPONSE FORM with edits.docx	2/28/2019 4:26 PM
Valsartan - Wholesale RECALL RESPONSE FORM with edits.docx	2/28/2019 4:25 PM
DPress Release Form - rev 01Mar2019.doc	3/1/2019 11:09 AM
Recall Questionnaires VFSA17007-A.DOCX	3/11/2019 1:17 AM
VALSARTAN (2) URGENT DRUG RECALL LETTER Draft_03-04-19.docx	3/4/2019 2:14 PM
VALSARTAN (2) URGENT DRUG RECALL LETTER Draft_03-04-19.docx	3/4/2019 2:14 PM
Press Release 2 draft 03-04-19.docx	3/4/2019 2:45 PM
Attachment B of Valsartan containing products for the failure reported in content of N	12/28/2018 7:38 AM
Attachment # 1 Manufacturing and distribution details.docx	12/28/2018 8:01 AM
Response to Internal Audit (PV and DC) Observations 07092012.docx	7/9/2012 3:14 PM
Draft follow up FAR for Valsartan containing drug product batch reported for more ac	1/25/2019 3:36 PM
Draft Follow Up FAR for Valsartan containaing products for the failure reported in con	12/26/2018 11:50 AM
Attachment 2 Unit I and 9 sartan products and process changes.pdf	3/29/2019 11:51 AM
List of Aurolife products in which Aurobindo India API is used.docx	6/4/2018 2:01 PM
Procedure of Monitoring Post Marketing RLD Update.pdf	6/5/2018 9:15 AM
Lucid LM#s.docx	7/25/2018 10:14 AM
API - Reduced Testing Proposals.doc	6/12/2012 3:42 PM
Annexure 3-4 Revised BPCRs of Stage-II and API.pdf	3/4/2019 5:22 AM
Annexure-3.5 Training records.pdf	3/4/2019 3:08 PM
4. Aurobindo.pdf	2/19/2016 6:57 AM
RE FDA Inspection details and DMF status.msg	2/19/2016 7:17 AM
Valsartan Tablets Placebo.pdf	5/8/2019 12:25 PM
RE FDA Inspection details and DMF status.msg	2/19/2016 7:17 AM
4. Aurobindo.pdf	2/19/2016 6:57 AM

